Associations - Gilotrif (afatinib)

EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1
No biomarker	Lung Non-Small Cell Squamous Cancer	No biomarker	Lung Non-Small Cell Squamous Cancer	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1
No biomarker	Oral Cancer	No biomarker	Oral Cancer	afatinib Sensitive: A2 - Guideline afatinib Sensitive : A2	afatinib Sensitive: A2 - Guideline afatinib Sensitive : A2
No biomarker	Oropharyngeal Cancer	No biomarker	Oropharyngeal Cancer	afatinib Sensitive: A2 - Guideline afatinib Sensitive : A2	afatinib Sensitive: A2 - Guideline afatinib Sensitive : A2
EGFR S768I	Non Small Cell Lung Cancer	EGFR S768I	Non Small Cell Lung Cancer	afatinib Sensitive: A2 - Guideline afatinib Sensitive : A2	afatinib Sensitive: A2 - Guideline afatinib Sensitive : A2
EGFR G719X	Non Small Cell Lung Cancer	EGFR G719X	Non Small Cell Lung Cancer	afatinib Sensitive: A2 - Guideline afatinib Sensitive : A2	afatinib Sensitive: A2 - Guideline afatinib Sensitive : A2
EGFR L861Q	Non Small Cell Lung Cancer	EGFR L861Q	Non Small Cell Lung Cancer	afatinib Sensitive: A2 - Guideline afatinib Sensitive : A2	afatinib Sensitive: A2 - Guideline afatinib Sensitive : A2
HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	afatinib Resistant: A2 - Guideline afatinib Resistant : A2	afatinib Resistant: A2 - Guideline afatinib Resistant : A2
EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	afatinib Sensitive: A2 - Guideline afatinib Sensitive : A2	afatinib Sensitive: A2 - Guideline afatinib Sensitive : A2
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	afatinib Sensitive: B - Late Trials afatinib Sensitive : B	afatinib Sensitive: B - Late Trials afatinib Sensitive : B
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	afatinib Sensitive: B - Late Trials afatinib Sensitive : B	afatinib Sensitive: B - Late Trials afatinib Sensitive : B
EGFR mutation	Lung Adenocarcinoma	EGFR mutation	Lung Adenocarcinoma	afatinib Sensitive: B - Late Trials afatinib Sensitive : B	afatinib Sensitive: B - Late Trials afatinib Sensitive : B
EGFR L858R + EGFR T790M	Non Small Cell Lung Cancer	EGFR L858R + EGFR T790M	Non Small Cell Lung Cancer	osimertinib + afatinib Sensitive: B - Late Trials osimertinib + afatinib Sensitive : B	osimertinib + afatinib Sensitive: B - Late Trials osimertinib + afatinib Sensitive : B
EGFR exon 19 deletion	Lung Adenocarcinoma	EGFR exon 19 deletion	Lung Adenocarcinoma	afatinib Sensitive: B - Late Trials afatinib Sensitive : B	afatinib Sensitive: B - Late Trials afatinib Sensitive : B
EGFR amplification	Squamous Cell Carcinoma of Head and Neck	EGFR amplification	Squamous Cell Carcinoma of Head and Neck	afatinib Sensitive: B - Late Trials afatinib Sensitive : B	afatinib Sensitive: B - Late Trials afatinib Sensitive : B
ERBB3-L	Squamous Cell Carcinoma of Head and Neck	ERBB3-L	Squamous Cell Carcinoma of Head and Neck	afatinib Sensitive: B - Late Trials afatinib Sensitive : B	afatinib Sensitive: B - Late Trials afatinib Sensitive : B
CDKN2A negative	Squamous Cell Carcinoma of Head and Neck	CDKN2A negative	Squamous Cell Carcinoma of Head and Neck	afatinib Sensitive: B - Late Trials afatinib Sensitive : B	afatinib Sensitive: B - Late Trials afatinib Sensitive : B
PTEN overexpression	Squamous Cell Carcinoma of Head and Neck	PTEN overexpression	Squamous Cell Carcinoma of Head and Neck	afatinib Sensitive: B - Late Trials afatinib Sensitive : B	afatinib Sensitive: B - Late Trials afatinib Sensitive : B
ERBB4 G668V	Lung Non-Small Cell Squamous Cancer	ERBB4 G668V	Lung Non-Small Cell Squamous Cancer	afatinib Sensitive: B - Late Trials afatinib Sensitive : B	afatinib Sensitive: B - Late Trials afatinib Sensitive : B
EGFR R1052K	Lung Non-Small Cell Squamous Cancer	EGFR R1052K	Lung Non-Small Cell Squamous Cancer	afatinib Sensitive: B - Late Trials afatinib Sensitive : B	afatinib Sensitive: B - Late Trials afatinib Sensitive : B
HER-2 E395K	Lung Non-Small Cell Squamous Cancer	HER-2 E395K	Lung Non-Small Cell Squamous Cancer	afatinib Sensitive: B - Late Trials afatinib Sensitive : B	afatinib Sensitive: B - Late Trials afatinib Sensitive : B
HER-2 Q57R	Lung Non-Small Cell Squamous Cancer	HER-2 Q57R	Lung Non-Small Cell Squamous Cancer	afatinib Sensitive: B - Late Trials afatinib Sensitive : B	afatinib Sensitive: B - Late Trials afatinib Sensitive : B
EGFR L858R	Lung Adenocarcinoma	EGFR L858R	Lung Adenocarcinoma	afatinib Sensitive: B - Late Trials afatinib Sensitive : B	afatinib Sensitive: B - Late Trials afatinib Sensitive : B
EGFR mutation	Esophageal Squamous Cell Carcinoma	EGFR mutation	Esophageal Squamous Cell Carcinoma	afatinib Sensitive: C1 - Off-label afatinib Sensitive : C1	afatinib Sensitive: C1 - Off-label afatinib Sensitive : C1
EGFR mutation	Gastric Cancer	EGFR mutation	Gastric Cancer	afatinib Sensitive: C1 - Off-label afatinib Sensitive : C1	afatinib Sensitive: C1 - Off-label afatinib Sensitive : C1
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	cetuximab + afatinib Sensitive: C2 – Inclusion Criteria cetuximab + afatinib Sensitive : C2	cetuximab + afatinib Sensitive: C2 – Inclusion Criteria cetuximab + afatinib Sensitive : C2
EGFR mutation	Lung Adenocarcinoma	EGFR mutation	Lung Adenocarcinoma	bevacizumab + afatinib Sensitive: C2 – Inclusion Criteria bevacizumab + afatinib Sensitive : C2	bevacizumab + afatinib Sensitive: C2 – Inclusion Criteria bevacizumab + afatinib Sensitive : C2
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	afatinib + selumetinib Sensitive: C2 – Inclusion Criteria afatinib + selumetinib Sensitive : C2	afatinib + selumetinib Sensitive: C2 – Inclusion Criteria afatinib + selumetinib Sensitive : C2
HER-2 amplification	Non Small Cell Lung Cancer	HER-2 amplification	Non Small Cell Lung Cancer	afatinib Sensitive: C2 – Inclusion Criteria afatinib Sensitive : C2	afatinib Sensitive: C2 – Inclusion Criteria afatinib Sensitive : C2

Gilotrif (afatinib)

Associations
(227)

Associations
(227)

Gilotrif (afatinib)

Associations(227)

Associations(227)

Associations
(227)

Associations
(227)